Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Indian Council of Medical Research (ICMR), Ministry of Health & Family Welfare (MOHFW), Govt. of India, Govt. of Madhya Pradesh and Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies), today, announced India’s first public-private-partnership agreement for Malaria Free India and other innovation in preventive health. This was announced by Dr Soumya Swaminathan, Director General –  ICMR, Principal Secretary Health Mrs. Gauri Singh Govt of Madhya Pradesh and Dilip Shanghvi, Managing Director, Sun Pharma as a unique effort to draw public – private sector collaboration in promoting  preventive health measures. The publicprivate-partnership stakeholders will jointly undertake malaria control & elimination programme by setting-up Management & Technical Committees to provide oversight for disease surveillance & elimination.

    [adsense:336x280:8701650588]

  • Lupin and its US subsidiary have re-introduced Methergine (methylergonovine maleate) oral tablets 0.2mg for the prevention and management of postpartum hemorrhage (PPH). Methergine is the only FDA-approved oral uterotonic and is a preferred oral agent in the management of PPH.

  • Accuray Incorporated, a radiation oncology company, announced the submission of its 510(k) premarket notification with the Food and Drug Administration (FDA) for the company’s Radixact Treatment Delivery System. Accuray also submitted 510(k) premarket notification for its treatment planning and data management systems, Precision Treatment Planning System and iDMS Data Management System.

  • ChemoCentryx, Inc., announced that the U.S. Food and Drug Administration (FDA) has awarded the Company a one-year grant of $500,000 to assist in the clinical development of CCX168, the Company's lead drug candidate for the treatment of patients with anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, or AAV. CCX168 is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.

  • OPKO Health, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted OPKO's resubmission on April 22, 2016 of the New Drug Application (NDA) for RAYALDEE® (calcifediol) for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

  • The constant emergence of viral outbreaks has become a permanent threat to human health. Last year, Zika virus infected thousands of people in the Americas. It is also associated to several cases of neurological disorders and has raised worldwide public health alerts. Now due to the urgency, researchers are detailing the characteristics of the virus to find solutions.

  • 28 April 2016
    Two Days National Symposium on Improving Healthoutcomes through Evidence based Practices

    Raghavendra Institute of Pharmaceutical Education and Research (RIPER) in association with ISPOR India – Andhra Pradesh Chapter, Indian Pharmaceutical Association (IPA) Anantapuramu Branch and KVSR Siddhartha College of Pharmaceutical Sciences

    A Two Days National Symposium on “Improving Healthoutcomes through Evidence based Practices” was organized by International Society for Pharmacoeconomics and Outcomes Research (ISPOR) India – Andhra Pradesh Chapter in association with Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Indian Pharmaceutical Association (IPA) Anantapuramu Branch, Kommareddy Venkata Sadasiva Rao (KVSR) Siddhartha College of Pharmaceutical Sciences and International Society for Pharmacoeconomics and Outcomes Research (ISPOR) RIPER Student Chapter on 22nd & 23rd April 2016 at KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh.

  • Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.The results were published Monday, April 25 in Journal of Clinical Investigation.

  • Collegium Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. 

Subscribe to Pharma News